Apixaban: Clinical Evidence & Trials
Apixaban is an anticoagulant that prevents blood clot formation and is used to treat or prevent deep vein thrombosis, pulmonary embolism, and atrial fibrillation.
Anticoagulants have landmark trial evidence for VTE treatment/prevention and stroke prevention in atrial fibrillation.
Evidence Strength
Level A (Strong) for AF stroke prevention, VTE treatment and prevention, DVT/PE prophylaxis. Warfarin only for mechanical heart valves and antiphospholipid syndrome.
Key Clinical Trial Findings
- •RE-LY (2009) — dabigatran 150mg superior to warfarin for AF stroke prevention; 110mg non-inferior with less bleeding
- •ROCKET-AF (2011) — rivaroxaban non-inferior to warfarin for AF; once-daily dosing advantage
- •ARISTOTLE (2011) — apixaban superior to warfarin for AF stroke prevention with significantly less major bleeding
- •ENGAGE-AF (2013) — edoxaban non-inferior to warfarin for AF with less bleeding
- •EINSTEIN trials — rivaroxaban non-inferior to LMWH/VKA for acute VTE treatment
- •Cochrane meta-analysis — LMWHs reduce VTE by >60% in surgical and medical prophylaxis settings
Numbers Needed to Treat (NNT)
AF stroke prevention: NNT ≈ 37 per year vs no anticoagulation; NNT ≈ 48 for DOACs vs warfarin (superiority outcomes). VTE prophylaxis post-orthopaedic surgery: NNT ≈ 12 for DVT prevention with LMWH vs no prophylaxis.
Guideline Recommendations
ESC/AHA/NICE guidelines recommend DOACs over warfarin for non-valvular AF and VTE in most patients. Warfarin remains first-line for mechanical heart valves and antiphospholipid syndrome (triple-positive APS). LMWHs preferred historically for cancer-associated VTE (DOACs now preferred by recent guidelines for many cancer types).
Conditions Treated with Apixaban
Questions about your medication?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant medications.
Use AI Symptom Checker →